Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Jonathan Powell
Johns Hopkins University, Department: Neurosciences
Should you be removed from our database? Contact us at [email protected]. Read more below.
Dracen Pharmaceuticals, Inc.
Other : JHU intellectual property rights
The SFIs that result from the equity and intellectual property rights are related in that their value could be affected by the research. Upon review by the institution, it was determined that Dr. Powell’s SFIs could directly and significantly affect the design, conduct or reporting of his research under this award.
Cell-targeted glutamine antagonists as a novel therapy for lymphoma
While a number of hematologic malignancies are cured using cytotoxic chemotherapy in younger patients, the cure rates of these diseases in older patients is much less sanguine. In addition, there are many side effects associated with these regimens that are magnified in older patients, making tolerability a significant issue. We and others have shown that the transcription factor proto-oncogene c-Myc drives certain cancers to change their energy metabolic requirements, and become ?glutamine addicted? for their growth and survival. Lymphoma is a clear example of such a cancer. Glutamine metabolism thus represents a therapeutic target for lymphoma. At the completion of our proposed studies we will have developed a novel, robust and safe inhibitor of glutamine metabolism that we hope to rapidly introduce into clinical trials.
Filed on June 18, 2019.
Tell us what you know about Jonathan Powell's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Jonathan Powell filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Jonathan Powell | Johns Hopkins University | Conflict of Interest | Dracen Pharmaceuticals, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.